U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab

Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering Complete response letter based on limited number of patients with 12-month drug exposure data in the accelerated approval submission; no other deficiencies were identified Definitive Phase 3…